{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:08:59Z","timestamp":1784034539646,"version":"3.55.0"},"reference-count":60,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Parkinson\u2019s disease (PD) is a complex condition and the requirements for managing both motor and non-motor symptoms evolve during the disease course. General neurologists following up people with PD should provide information, support and lifestyle advice, such as on exercise, with support from a multidisciplinary team. Levodopa remains the most effective and well-tolerated symptomatic treatment, but dose adjustments and adjunctive dopaminergic therapies can help with motor fluctuations. Clinicians should pay close attention to non-motor symptoms, including neuropsychiatric complications such as impulse-control disorders. The evidence base for managing non-motor symptoms is evolving. Involving the patient in the multidisciplinary follow-up of PD can help in managing symptoms unlikely to respond simply to dopamine replacement, including gait problems, falls and swallowing impairment. Clinicians should be open-minded about the diagnosis during follow-up and consider referring appropriate patients to specialists for device-aided therapies.<\/jats:p>","DOI":"10.1136\/pn-2025-004697","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:20:32Z","timestamp":1762971632000},"page":"331-339","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Parkinson\u2019s disease: the follow-up consultation"],"prefix":"10.1136","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7797-0756","authenticated-orcid":false,"given":"Christopher","family":"Kobylecki","sequence":"first","affiliation":[{"name":"Division of Neuroscience, University of Manchester, Manchester, UK"},{"name":"Manchester Centre for Clinical Neurosciences, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, Salford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"2026071405250890000_26.4.331.1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The Emerging Evidence of the Parkinson Pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"2026071405250890000_26.4.331.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-095610","article-title":"Global burden of Parkinson\u2019s disease from 1990 to 2021: a population-based study","volume":"15","author":"Li","year":"2025","journal-title":"BMJ Open"},{"key":"2026071405250890000_26.4.331.3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00218-x"},{"key":"2026071405250890000_26.4.331.4","unstructured":"Parkinson\u2019s UK . Newly diagnosed with Parkinson\u2019s. 2022. Available: https:\/\/www.parkinsons.org.uk\/information-and-support\/newly-diagnosed-parkinsons [Accessed 11 Jul 2025]."},{"key":"2026071405250890000_26.4.331.5","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.3233\/JPD-230224","article-title":"Parkinson\u2019s Nurses Are Crucial for the Management of Parkinson\u2019s Disease: 2007-2024","volume":"14","author":"Thomas","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"2026071405250890000_26.4.331.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5728-8"},{"key":"2026071405250890000_26.4.331.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30285-6"},{"key":"2026071405250890000_26.4.331.8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3233\/JPD-230277","article-title":"Advice to People with Parkinson\u2019s in My Clinic: Exercise","volume":"14","author":"Corcos","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"2026071405250890000_26.4.331.9","doi-asserted-by":"crossref","unstructured":"Rees J , Cooper P , Cruickshank G , et al . Eligibility to drive and neurology: the how and the why. Pract Neurol 2022. doi:10.1136\/practneurol-2021-003163","DOI":"10.1136\/practneurol-2021-003163"},{"key":"2026071405250890000_26.4.331.10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/mdc3.13676","article-title":"Driving Impairment in Movement Disorders","volume":"10","author":"Makhoul","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"2026071405250890000_26.4.331.11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7861\/clinmed.2020-0220","article-title":"Update on the diagnosis and management of Parkinson\u2019s disease","volume":"20","author":"Kobylecki","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"2026071405250890000_26.4.331.12","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/PL00007732","article-title":"Practical approach to quality of life in Parkinson\u2019s disease: the nurse\u2019s role","volume":"245 Suppl 1","author":"MacMahon","year":"1998","journal-title":"J Neurol"},{"key":"2026071405250890000_26.4.331.13","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.3233\/JPD-202096","article-title":"Challenges and Perspectives in the Management of Late-Stage Parkinson\u2019s Disease","volume":"10","author":"Fabbri","year":"2020","journal-title":"J Parkinsons Dis"},{"key":"2026071405250890000_26.4.331.14","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamaneurol.2018.4377","article-title":"Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease","volume":"76","author":"De Pablo-Fern\u00e1ndez","year":"2019","journal-title":"JAMA Neurol"},{"key":"2026071405250890000_26.4.331.15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1212\/WNL.0000000000002437","article-title":"Development and external validation of a prognostic model in newly diagnosed Parkinson disease","volume":"86","author":"Velseboer","year":"2016","journal-title":"Neurology"},{"key":"2026071405250890000_26.4.331.16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3233\/JPD-191763","article-title":"Ethnic Variation in the Manifestation of Parkinson\u2019s Disease: A Narrative Review","volume":"10","author":"Ben-Joseph","year":"2020","journal-title":"J Parkinsons Dis"},{"key":"2026071405250890000_26.4.331.17","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27372"},{"key":"2026071405250890000_26.4.331.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30036-3"},{"key":"2026071405250890000_26.4.331.19","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa","volume":"137","author":"Cilia","year":"2014","journal-title":"Brain (Bacau)"},{"key":"2026071405250890000_26.4.331.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809983"},{"key":"2026071405250890000_26.4.331.21","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial","volume":"384","author":"Gray","year":"2014","journal-title":"The Lancet"},{"key":"2026071405250890000_26.4.331.22","article-title":"Dopamine agonist therapy in early Parkinson\u2019s disease","volume":"2008","author":"Stowe","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2026071405250890000_26.4.331.23","unstructured":"National Institute for Health and Care Excellence . Parkinson\u2019s disease in adults: diagnosis and management. 2017."},{"key":"2026071405250890000_26.4.331.24","first-page":"e367","article-title":"Levodopa Response in Patients With Early Parkinson Disease: Further Observations of the LEAP Study","volume":"100","author":"Frequin","year":"2023","journal-title":"Neurology (ECronicon)"},{"key":"2026071405250890000_26.4.331.25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mdc3.14262","article-title":"Tremor Is Highly Responsive to Levodopa in Advanced Parkinson\u2019s Disease","volume":"12","author":"Swinnen","year":"2025","journal-title":"Mov Disord Clin Pract"},{"key":"2026071405250890000_26.4.331.26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40120-023-00486-5","article-title":"Clinical Use of On-Demand Therapies for Patients with Parkinson\u2019s Disease and OFF Periods","volume":"12","author":"Pahwa","year":"2023","journal-title":"Neurol Ther"},{"key":"2026071405250890000_26.4.331.27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.parkreldis.2014.09.013","article-title":"Characterizing motor and non-motor aspects of early-morning off periods in Parkinson\u2019s disease: an international multicenter study","volume":"20","author":"Rizos","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"2026071405250890000_26.4.331.28","doi-asserted-by":"crossref","DOI":"10.1186\/s40734-020-00087-6","article-title":"Objective measurement in Parkinson\u2019s disease: a descriptive analysis of Parkinson\u2019s symptom scores from a large population of patients across the world using the Personal KinetiGraph\u00ae","volume":"7","author":"Pahwa","year":"2020","journal-title":"J Clin Mov Disord"},{"key":"2026071405250890000_26.4.331.29","doi-asserted-by":"crossref","DOI":"10.1186\/s40734-016-0036-9","article-title":"Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson\u2019s disease","volume":"3","author":"Virmani","year":"2016","journal-title":"J Clin Mov Disord"},{"key":"2026071405250890000_26.4.331.30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/nmt-2018-0020","article-title":"Noninvasive options for \u201cwearing-off\u201d in Parkinson\u2019s disease: a clinical consensus from a panel of UK Parkinson\u2019s disease specialists","volume":"8","author":"Fackrell","year":"2018","journal-title":"Neurodegener Dis Manag"},{"key":"2026071405250890000_26.4.331.31","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/mds.30162","article-title":"Update on Treatments for Parkinson\u2019s Disease Motor Fluctuations \u2013 An International Parkinson and Movement Disorder Society Evidence\u2010Based Medicine Review","volume":"40","author":"de Bie","year":"2025","journal-title":"Mov Disord"},{"key":"2026071405250890000_26.4.331.32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamaneurol.2021.4736","article-title":"Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy","volume":"79","author":"Gray","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026071405250890000_26.4.331.33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00002826-199704000-00008","article-title":"Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson\u2019s disease patients: a double-blind single-dose study","volume":"20","author":"Merello","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"2026071405250890000_26.4.331.34","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22643"},{"key":"2026071405250890000_26.4.331.35","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23394"},{"key":"2026071405250890000_26.4.331.36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.parkreldis.2019.04.014","article-title":"Barriers to reporting non-motor symptoms to health-care providers in people with Parkinson\u2019s","volume":"64","author":"Hurt","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"2026071405250890000_26.4.331.37","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27602"},{"key":"2026071405250890000_26.4.331.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01429-0"},{"key":"2026071405250890000_26.4.331.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.02.001"},{"key":"2026071405250890000_26.4.331.40","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.65"},{"key":"2026071405250890000_26.4.331.41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005816"},{"key":"2026071405250890000_26.4.331.42","unstructured":"National Institute for Health and Care Excellence . Parkinson\u2019s disease quality standard QS164. 2018."},{"key":"2026071405250890000_26.4.331.43","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12646"},{"key":"2026071405250890000_26.4.331.44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.12968\/hmed.2013.74.3.160","article-title":"Managing impulse control behaviours in Parkinson\u2019s disease: practical guidelines","volume":"74","author":"Macphee","year":"2013","journal-title":"Br J Hosp Med"},{"key":"2026071405250890000_26.4.331.45","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.294"},{"key":"2026071405250890000_26.4.331.46","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20324"},{"key":"2026071405250890000_26.4.331.47","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000002350"},{"key":"2026071405250890000_26.4.331.48","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"2026071405250890000_26.4.331.49","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.parkreldis.2018.10.009","article-title":"Red flags phenotyping: A systematic review on clinical features in atypical parkinsonian disorders","volume":"59","author":"Bhidayasiri","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"2026071405250890000_26.4.331.50","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213499","article-title":"Stability and Accuracy of a Diagnosis of Parkinson Disease Over 10 Years","volume":"104","author":"R\u00e4ty","year":"2025","journal-title":"Neurology"},{"key":"2026071405250890000_26.4.331.51","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29066"},{"key":"2026071405250890000_26.4.331.52","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2012-000463"},{"key":"2026071405250890000_26.4.331.53","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00702-024-02782-2","article-title":"What was first and what is next in selecting device-aided therapy in Parkinson\u2019s disease? Balancing evidence and experience","volume":"131","author":"Phokaewvarangkul","year":"2024","journal-title":"J Neural Transm (Vienna)"},{"key":"2026071405250890000_26.4.331.54","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3233\/JPD-240193","article-title":"Winding Back the Clock on Advanced Therapies: It\u2019s Time to Get Smart","volume":"14","author":"Georgiades","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"2026071405250890000_26.4.331.55","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j1951","article-title":"Parkinson\u2019s disease: summary of updated NICE guidance","volume":"358","author":"Rogers","year":"2017","journal-title":"BMJ"},{"key":"2026071405250890000_26.4.331.56","doi-asserted-by":"crossref","unstructured":"Schini M , Vilaca T , Poku E , et al . The risk of hip and non-vertebral fractures in patients with Parkinson\u2019s disease and parkinsonism: A systematic review and meta-analysis. Bone 2020;132. doi:10.1016\/j.bone.2019.115173","DOI":"10.1016\/j.bone.2019.115173"},{"key":"2026071405250890000_26.4.331.57","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0543-5"},{"key":"2026071405250890000_26.4.331.58","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afaf052","article-title":"Assessing and managing bone health and fracture risk in Parkinson\u2019s disease: the BONE PARK 2 protocol","volume":"54","author":"Naylor","year":"2025","journal-title":"Age Ageing"},{"key":"2026071405250890000_26.4.331.59","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-240272","article-title":"Parkinson\u2019s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"2026071405250890000_26.4.331.60","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JPD-225060","article-title":"Pharmacological Treatment of Tremor in Parkinson\u2019s Disease Revisited","volume":"13","author":"Pirker","year":"2023","journal-title":"J Parkinsons Dis"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2025-004697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:25:40Z","timestamp":1784031940000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2025-004697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/pn-2025-004697"],"URL":"https:\/\/doi.org\/10.1136\/pn-2025-004697","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}